multitarget stool RNA; mt-sRNA (Colosense)
Jump to navigation
Jump to search
Indications
- screening for colon cancer (investigational 2023)
Procedure
- tests patients' stool for
Interpretation
- among average-risk patients, sensitivity for multitarget stool RNA is
- 94% for colorectal cancer
- 100% for stage I/II colorectal cancer
- 92% for stage III/IV colorectal cancer
- 65% for >= 10 adenomas or lesions with high-grade dysplasia
- 47% for tubulovillous adenomas
- 42% for serrated adenomas or tubular adenomas >= 1 cm[1]
- 94% for colorectal cancer
- specificity for multitarget stool RNA is 85%[1]
- 88% specificity for no lesions on colonoscopy
More general terms
References
- ↑ 1.0 1.1 1.2 Barnell EK, Wurtzler EM, La Rocca J et al Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. Published online October 23, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37870871 https://jamanetwork.com/journals/jama/fullarticle/2811133